Conning Inc. held its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, Holdings Channel reports. The firm owned 2,110 shares of the biopharmaceutical company’s stock at the end of the second quarter. Conning Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,036,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of REGN. BlackRock Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares in the last quarter. Janus Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Regeneron Pharmaceuticals by 36.8% in the first quarter. Bank of New York Mellon Corp now owns 881,867 shares of the biopharmaceutical company’s stock worth $341,733,000 after buying an additional 237,157 shares in the last quarter. Institutional investors and hedge funds own 67.16% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at 472.57 on Wednesday. The stock’s 50 day moving average price is $493.07 and its 200 day moving average price is $429.52. The firm has a market capitalization of $50.11 billion, a price-to-earnings ratio of 47.41 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period last year, the company earned $2.82 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Position Maintained by Conning Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-position-maintained-by-conning-inc/1494472.html.

A number of equities research analysts recently weighed in on REGN shares. Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the company from $375.00 to $484.00 in a research note on Friday, May 5th. Vetr cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 price objective on the stock. in a research note on Monday, May 1st. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Piper Jaffray Companies lifted their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research note on Tuesday, June 20th. Finally, BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $488.23.

In other news, major shareholder Sanofi acquired 136,050 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was acquired at an average cost of $478.17 per share, for a total transaction of $65,055,028.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,922 shares of company stock valued at $27,383,105. 10.40% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.